Cell & Gene Therapy Asia Summit 2019(China)
The world's precision medicine market has surpassed US $ 60 billion and will grow by about 15% from 2015 to 2020. In 2016, China announced precision medicine as part of its five-year plan, with an expected investments of 60 billion yuan (or more than $9 billion) for research. Nearly 40 countries have their own version of a precision medicine initiative, but, China’s is the largest. China Precision Medicine was included in one hundred major projects in the "13th Five-Year Plan". In addition, in the 19th CPC National Congress, once again emphasize "people health", strive to promote local precision medicine, which aims to advance China into the first tier of international precision medical services.
Want a window on the future of biopharma? Look no further than cell and gene therapy. This is one of the most complex fields of biotherapeutics – but one with huge growth potential. Its promise to deliver precision medicines for challenging disease areas ranging from oncology to rare genetic disorders is what makes it so exciting. China is quickly becoming a world leader in biopharma, with rapid build-out of gene and cell therapy production capacity and a robust pipeline of drugs in development.
In December 2017, the CFDA released "Guiding Principles for the Research and Evaluation of Cell Therapy Products" for trial implementation. This hotly anticipated move now adds cell therapies – such as stem cells and chimeric antigen receptor therapies – under the umbrella of CFDA reforms that are aligning China's drug regulations with global drug markets. The guidelines set out standards for the approval of clinical trials for cell therapies and opens the door to a viable path to commercialization of cell therapies to be regulated by the CFDA, much like other new drugs.
To make this plan a reality, China needs the right tools, technologies and people to maintain its momentum. China is reshaping its regulatory landscape, upgrading manufacturing capabilities, and attracting the talent needed to deliver targeted therapies to patients. Take CAR-T cell therapies, for example. Only a handful of these products have been approved to date, but the pipeline is looking healthy – and the pipeline is promising in China. According to the Financial Times in April 2018, there were 116 CAR-Ttrials ongoing in China compared with 96 in the US and 15 in Europe.
The Cell & Gene Therapy Asia Summit 2019(China) will be an excellent opportunity for the CGTprofessionals from around the world to gather, engage, share and discuss the progress, needs and challenges with manufacturing and commercialing cell & gene therayp products in China . This two-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first event of its kind dedicated solely to facilitating connections in this sector. Combined, these meetings attract over 450 attendees, fostering key partnerships through one-on-one meetings while highlighting the significant clinical and commercial progress in the field.
We are looking forward to meeting you at Cell & Gene Therapy Asia Summit 2019(China) in China!